Artificial intelligence (AI) is emerging as a transformative tool in the diagnosis of bladder cancer, offering the potential to enhance accuracy, consistency, and early detection.
This narrative review aimed to summarize and critically appraise recent developments in AI applications across diagnostic modalities, based on studies identified through PubMed, Scopus, and Google Scholar up to April 2025. Evidence shows that deep learning algorithms applied to cystoscopy improve lesion detection, inc
Bladder cancer (BC) remains one of the most common malignancies worldwide, ranking as the 10th most prevalent cancer globally [1] . According to GLOBOCAN 2018, approximately 500,000 new cases of BC are diagnosed annually, with a significant proportion of the burden occurring in men [1,2] .
The male-to-female ratio for incidence is nearly 3:1, reflecting both biological differences and variations in exposure to established risk factors such as smoking and occupational carcinogens [2] . In addition to its incidence, BC is associated with one of the highest recurrence rates among solid tumors
capable of learning from large
underscore AI’s promising role in improving diagnostic precision and workflow efficiency, its clinical adoption requires addressing issues of data quality, algorithm transparency, and ethical governance.
Future research should focus on developing explainable and validated models through multicenter collaborations between clinicians and data scientists to facilitate safe and reliable integration of AI into routine bladder cancer diagnosis.
Categories: Urology, Healthcare Technology, Oncology Keywords: artificial intelligence, cystoscopy, histopathology, machine learning, urinary bladder neoplasms Introduction And Background Bladder cancer (BC) remains one of the most common malignancies wo
. Each included study was appraised for methodological quality, sample size, data source reliability, validation strategy, and reporting of key performance metrics such as accuracy, sensitivity, specificity, and area under the curve (AUC).
For synthesis, studies were thematically categorized into four domains of AI application: (i) cystoscopy and imaging algorithms for lesion detection and characterization, (ii) histopathology and cytology-computer- assisted image analysis for grading and staging, (iii) urinary biomarkers and genomics-predictive models integrating molecular and genomic data, and (iv) CDS, AI-based diagnostic aid, and risk stratification tools.
This structured approach enable
s This review highlights that AI is emerging as a valuable tool for improving BC diagnosis across cystoscopic imaging, histopathology, urinary biomarkers, and genomic profiling.
Evidence from existing studies suggests that AI can enhance accuracy, reduce inter-observer variability, and support earlier detection when integrated into conventional diagnostic pathways. Importantly, in regions such as Pakistan, where diagnostic resources are limited and disease burden is high, AI-assisted tools could